Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 3/20 | 0.56 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.48 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.48 |
| ▸ | MMP13 | P45452 | 1/20 | 0.47 |
| ▸ | EPHX2 | P34913 | 4/20 | 0.46 |
| ▸ | FAAH | O00519 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | MLYCD | O95822 | 1/20 | 0.44 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.44 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5529978 | 1.00 | AR (0.56) | ARGRIN1GRIN2BMMP13EPHX2 | |
| SCHEMBL5525223 | 0.88 | SMN1; SMN2 (0.52) | GRIN1GRIN2BMMP13KMT2AALDH1A1 | |
| SCHEMBL5516494 | 0.88 | SMN1; SMN2 (0.47) | ARMMP13EPHX2FAAHKMT2A | |
| SCHEMBL5516498 | 0.88 | SMN1; SMN2 (0.47) | ARMMP13EPHX2FAAHKMT2A | |
| SCHEMBL5525221 | 0.88 | SMN1; SMN2 (0.52) | GRIN1GRIN2BMMP13KMT2AALDH1A1 | |
| SCHEMBL5532830 | 0.86 | AR (0.52) | ARGRIN1GRIN2BMMP13EPHX2 | |
| SCHEMBL5532824 | 0.86 | AR (0.52) | ARGRIN1GRIN2BMMP13EPHX2 | |
| SCHEMBL8285679 | 0.85 | PARP15 (0.50) | ARMMP13GABRA5 | |
| SCHEMBL14451499 | 0.85 | PARP15 (0.50) | ARMMP13GABRA5 | |
| SCHEMBL5522549 | 0.85 | AR (0.54) | ARMMP13EPHX2KMT2AGABRA5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070167452-A1 | Therapeutic amide derivatives | PFIZER, INC. | 2007-07-19 | — | — | US | claimed |
| EP-1716100-A2 | THERAPEUTIC AMIDE DERIVATIVES | Pfizer, Inc. (US) | 2006-11-02 | — | — | EP | claimed |
| WO-2005080317-A2 | THERAPEUTIC AMIDE DERIVATIVES | PFIZER JAPAN, INC. (JP) | 2005-09-01 | — | — | WO | claimed |
| US-20070167452-A1 | Therapeutic amide derivatives | PFIZER, INC. | 2007-07-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070167452-A1 | Therapeutic amide derivatives | GRIN1, GRIN2B, GRIN3A | AR 1299/4885GRIN1 1/4885GRIN2B 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.